{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T19:26:38Z","timestamp":1779909998653,"version":"3.53.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,1,14]],"date-time":"2021-01-14T00:00:00Z","timestamp":1610582400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,1,14]],"date-time":"2021-01-14T00:00:00Z","timestamp":1610582400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      The superior accuracy and sensitivity of\n                      <jats:sup>18<\/jats:sup>\n                      F-FDG-PET\/CT in comparison to morphological imaging alone leads to an upstaging in up to 30% of lymphoma patients. Novel digital PET\/CT scanners might enable to reduce administered tracer activity or scan time duration while maintaining diagnostic performance; this might allow for a higher patient throughput or a reduced radiation exposure, respectively. In particular, the radiation exposure reduction is of interest due to the often young age and high remission rate of lymphoma patients.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Twenty patients with (suspected) lymphoma (6 for initial staging, 12 after systemic treatment, 2 in suspicion of recurrence) sequentially underwent\n                      <jats:sup>18<\/jats:sup>\n                      F-FDG-PET\/CT examinations on a digital PET\/CT (Siemens Biograph Vision) with a total scan time duration of 15\u2009min (reference acquisition protocol) and 5\u2009min (reduced acquisition protocol) using continuous-bed-motion. Both data sets were reconstructed using either standalone time of flight (TOF) or in combination with point spread function (PSF), each with 2 and 4 iterations. Lesion detectability by blinded assessment (separately for supra- and infradiaphragmal nodal lesions and for extranodal lesions), lesion image quantification, and image noise were used as metrics to assess diagnostic performance. Additionally, Deauville Score was compared for all patients after systemic treatment.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>All defined regions were correctly classified in the images acquired with reduced emission time, and therefore, no changes in staging were observed. Lesion quantification was acceptable, that is, mean absolute percentage deviation of maximum and peak standardized uptake values were 6.8 and 6.4% (derived from 30 lesions). A threefold reduction of scan time duration led to an increase in image noise from 7.1 to 11.0% (images reconstructed with 4 iterations) and from 4.7 to 7.2% (images reconstructed with 2 iterations). No deviations in Deauville Score were observed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>These results suggest that scan time duration or administered tracer activity can be reduced threefold without compromising diagnostic performance. Especially a reduction of administered activity might allow for a lower radiation exposure and better health economics. Larger trials are warranted to confirm our results.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-020-07723-2","type":"journal-article","created":{"date-parts":[[2021,1,14]],"date-time":"2021-01-14T06:03:19Z","timestamp":1610604199000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Evaluation of 18F-FDG PET\/CT images acquired with a reduced scan time duration in lymphoma patients using the digital biograph vision"],"prefix":"10.1186","volume":"21","author":[{"given":"Manuel","family":"Weber","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter","family":"Jentzen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Regina","family":"Hofferber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Herrmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang Peter","family":"Fendler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Rischpler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lale","family":"Umutlu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Conti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro Fragoso","family":"Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Sraieb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Kersting","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,14]]},"reference":[{"issue":"27","key":"7723_CR1","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson BD, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32(27):3059\u201368.","journal-title":"J Clin Oncol"},{"issue":"20","key":"7723_CR2","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.1200\/JCO.2017.76.8093","volume":"36","author":"U Duhrsen","year":"2018","unstructured":"Duhrsen U, et al. Positron emission tomography-guided therapy of aggressive non-Hodgkin lymphomas (PETAL): a multicenter, randomized phase III trial. J Clin Oncol. 2018;36(20):2024\u201334.","journal-title":"J Clin Oncol"},{"issue":"10","key":"7723_CR3","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1007\/s00247-005-1505-8","volume":"35","author":"MJ Gelfand","year":"2005","unstructured":"Gelfand MJ, et al. Pre-medication to block [(18) F] FDG uptake in the brown adipose tissue of pediatric and adolescent patients. Pediatr Radiol. 2005;35(10):984\u201390.","journal-title":"Pediatr Radiol"},{"issue":"2","key":"7723_CR4","first-page":"170","volume":"44","author":"C Cohade","year":"2003","unstructured":"Cohade C, et al. Uptake in supraclavicular area fat (\"USA-Fat\"): description on 18F-FDG PET\/CT. J Nucl Med. 2003;44(2):170\u20136.","journal-title":"J Nucl Med"},{"issue":"Suppl 1","key":"7723_CR5","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s00259-017-3690-8","volume":"44","author":"SF Barrington","year":"2017","unstructured":"Barrington SF, Kluge R. FDG PET for therapy monitoring in Hodgkin and non-Hodgkin lymphomas. Eur J Nucl Med Mol Imaging. 2017;44(Suppl 1):97\u2013110.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"7723_CR6","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1007\/s00259-014-2961-x","volume":"42","author":"R Boellaard","year":"2015","unstructured":"Boellaard R, et al. FDG PET\/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2015;42(2):328\u201354.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7723_CR7","doi-asserted-by":"crossref","unstructured":"van Sluis J, et al. Image quality and semi-quantitative measurements of the Siemens biograph vision PET\/CT: initial experiences and comparison with Siemens biograph mCT PET\/CT. J Nucl Med. 2020;61(1):129\u2013135.","DOI":"10.2967\/jnumed.119.227801"},{"issue":"1","key":"7723_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40658-019-0269-4","volume":"7","author":"S Gnesin","year":"2020","unstructured":"Gnesin S, et al. Phantom-based image quality assessment of clinical (18) F-FDG protocols in digital PET\/CT and comparison to conventional PMT-based PET\/CT. EJNMMI Phys. 2020;7(1):1.","journal-title":"EJNMMI Phys"},{"key":"7723_CR9","doi-asserted-by":"crossref","unstructured":"Surti S, et al. Benefit of improved performance with state-of-the art digital PET\/CT for lesion detection in oncology. J Nucl Med. 2020;61(11):1684\u20131690.","DOI":"10.2967\/jnumed.120.242305"},{"key":"7723_CR10","doi-asserted-by":"crossref","unstructured":"van Sluis J, et al. Image quality and activity optimization in oncological (18) F-FDG PET using the digital biograph vision PET\/CT. J Nucl Med. 2019.","DOI":"10.2967\/jnumed.119.234351"},{"issue":"1020","key":"7723_CR11","doi-asserted-by":"publisher","first-page":"e1166","DOI":"10.1259\/bjr\/25026140","volume":"85","author":"DJ Shah","year":"2012","unstructured":"Shah DJ, Sachs RK, Wilson DJ. Radiation-induced cancer: a modern view. Br J Radiol. 2012;85(1020):e1166\u201373.","journal-title":"Br J Radiol"},{"key":"7723_CR12","doi-asserted-by":"crossref","unstructured":"Rauscher I, et al. Can the injected dose be reduced in (68) Ga-PSMA-11 PET\/CT maintaining high image quality for lesion detection? J Nucl Med. 2020;61(2):189\u2013193.","DOI":"10.2967\/jnumed.119.227207"},{"key":"7723_CR13","unstructured":"Bramer, A., Phantom study for optimization [18F] FDG imaging of lymphoma using Biograph Vision PET\/CT., in Department for Nuclear medicine. 2019, University Duisburg-Essen."},{"issue":"Suppl 1","key":"7723_CR14","first-page":"257","volume":"47","author":"P Fragoso Costa","year":"2020","unstructured":"Fragoso Costa P, et al. Emission time reduction for 2-[18F] FDG examinations in lymphoma patients with a PET\/CT with SiPM - a feasibility phantom study (EPS-093); European Association of Nuclear Medicine October 22\u201330, 2020 Virtual. Eur J Nucl Med Mol Imaging. 2020;47(Suppl 1):257.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"7723_CR15","doi-asserted-by":"publisher","first-page":"72","DOI":"10.2967\/jnmt.110.081661","volume":"39","author":"A Nagaki","year":"2011","unstructured":"Nagaki A, Onoguchi M, Matsutomo N. Patient weight-based acquisition protocols to optimize (18) F-FDG PET\/CT image quality. J Nucl Med Technol. 2011;39(2):72\u20136.","journal-title":"J Nucl Med Technol"},{"issue":"2","key":"7723_CR16","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1148\/radiol.12121385","volume":"267","author":"M Viner","year":"2013","unstructured":"Viner M, et al. Liver SULmean at FDG PET\/CT: interreader agreement and impact of placement of volume of interest. Radiology. 2013;267(2):596\u2013601.","journal-title":"Radiology"},{"issue":"5","key":"7723_CR17","doi-asserted-by":"publisher","first-page":"608","DOI":"10.2967\/jnumed.118.209544","volume":"60","author":"BF Kurland","year":"2019","unstructured":"Kurland BF, et al. Test-retest reproducibility of (18) F-FDG PET\/CT uptake in Cancer patients within a qualified and calibrated local network. J Nucl Med. 2019;60(5):608\u201314.","journal-title":"J Nucl Med"},{"key":"7723_CR18","volume-title":"Evaluation of 68Ga-PSMA PET\/CT images acquired with a reduced scan time duration in prostate Cancer patients using the digital biograph vision","author":"M Weber","year":"2020","unstructured":"Weber, M., et al., Evaluation of 68Ga-PSMA PET\/CT images acquired with a reduced scan time duration in prostate Cancer patients using the digital biograph vision. 2020."},{"issue":"1","key":"7723_CR19","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s40658-016-0144-5","volume":"3","author":"M Conti","year":"2016","unstructured":"Conti M, Eriksson L. Physics of pure and non-pure positron emitters for PET: a review and a discussion. EJNMMI Phys. 2016;3(1):8.","journal-title":"EJNMMI Phys"},{"issue":"6","key":"7723_CR20","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/j.clml.2014.07.003","volume":"14","author":"W Haque","year":"2014","unstructured":"Haque W, et al. Radiation therapy is an effective modality in the treatment of mantle cell lymphoma, even in heavily pretreated patients. Clin Lymphoma Myeloma Leuk. 2014;14(6):474\u20139.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"6","key":"7723_CR21","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1007\/s002590100537","volume":"28","author":"K Kubota","year":"2001","unstructured":"Kubota K, et al. Advantage of delayed whole-body FDG-PET imaging for tumour detection. Eur J Nucl Med. 2001;28(6):696\u2013703.","journal-title":"Eur J Nucl Med"},{"issue":"3","key":"7723_CR22","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1007\/s002590050381","volume":"26","author":"AR Boerner","year":"1999","unstructured":"Boerner AR, et al. Optimal scan time for fluorine-18 fluorodeoxyglucose positron emission tomography in breast cancer. Eur J Nucl Med. 1999;26(3):226\u201330.","journal-title":"Eur J Nucl Med"},{"issue":"1","key":"7723_CR23","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s40658-018-0207-x","volume":"5","author":"I Sonni","year":"2018","unstructured":"Sonni I, et al. Initial experience with a SiPM-based PET\/CT scanner: influence of acquisition time on image quality. EJNMMI Phys. 2018;5(1):9.","journal-title":"EJNMMI Phys"},{"issue":"4","key":"7723_CR24","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/s11307-009-0200-9","volume":"11","author":"BJ Fueger","year":"2009","unstructured":"Fueger BJ, et al. Comparison of CT, PET, and PET\/CT for staging of patients with indolent non-Hodgkin's lymphoma. Mol Imaging Biol. 2009;11(4):269\u201374.","journal-title":"Mol Imaging Biol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-020-07723-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-020-07723-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-020-07723-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,14]],"date-time":"2021-01-14T06:10:03Z","timestamp":1610604603000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-020-07723-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,14]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["7723"],"URL":"https:\/\/doi.org\/10.1186\/s12885-020-07723-2","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-46922\/v1","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-46922\/v2","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-46922\/v3","asserted-by":"object"}]},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,14]]},"assertion":[{"value":"23 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The retrospective analysis of available patient data was performed in accordance with the declaration of Helsinki and approved by the local ethics committee (Ethics committee, University Duisburg-Essen, faculty of medicine; reference number: 20\u20139204-BO).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Manuel Weber, Regina Hofferber, Axel Wetter, David Kersting, and Pedro Fragoso Costa have nothing to disclose. W. Jentzen received research funding from Siemens Healthineers.Ken Herrmann reports personal fees from Bayer, personal fees and other from Sofie Biosciences, personal fees from SIRTEX, non-financial support from ABX, personal fees from Adacap, personal fees from Curium, personal fees from Endocyte, grants and personal fees from BTG, personal fees from IPSEN, personal fees from Siemens Healthineers, personal fees from GE Healthcare, personal fees from Amgen, personal fees from Novartis, personal fees from ymabs, outside the submitted work; Wolfgang P. Fendler is a consultant for Endocyte and BTG, and he received personal fees from RadioMedix outside of the submitted work.Maurizio Conti is an employee of Siemens Medical Solutions USA.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"62"}}